Efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer: a meta-analysis of RCTs
Abstract Introduction HER2-positive breast cancer is an aggressive subtype that benefits from targeted therapies. According to the Chinese Society of Clinical Oncology (CSCO) guidelines and the National Comprehensive Cancer Network (NCCN), the combination of trastuzumab (H) with pertuzumab (P) and n...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2026-01-01
|
| Schriftenreihe: | Systematic Reviews |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s13643-025-03058-w |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|